Safety and clinical activity of invikafusp alfa, a selective T cell activator, against antigen-rich solid tumors
1470. START001: A Phase 1/2 study of Invikafusp alfa (STAR0602), a first-in-class TCR β chain-targeted bispecific antibody, as monotherapy in patients with antigen-rich solid tumors resistant to anti-PD(L)1
James Gulley (National Cancer Institute, Bethesda, MD, USA) presented results from the STARt-001 trial, phase 1/2 study investigating invikafusp alfa, a dual T cell agonist for the treatment of anti-PD(L)1-resistant, antigen-rich solid tumors. Invikafusp alfa is a selective T cell activator consisting of a selective Vβ T ...